Autopsy report · NCT02218216

TBI MR Study 3 Houston Methodist

“Sponsor terminated study early to start a larger feasability study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 2 months before it stopped.
• 16 participants enrolled.
• Results were posted on the registry 1 year 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

GE Healthcare

Sponsor type

Industry

Conditions

Traumatic Brain Injury

Interventions

MRI Diagnostic

Participants

16

Sites

1

Countries

United States

Trials that died the same way

• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (87% match in meaning)
• Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
  “Sponsor decided to terminate study early” (86% match in meaning)
• Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
  “Sponsor terminated study” (86% match in meaning)
• TransGrade Multimodal Neuromodulation of the Dorsal Root Ganglion Ensemble for Refractory Neuropathic Pain
  “Study terminated early at the request of Sponsors.” (85% match in meaning)
• An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
  “The sponsor decided to terminate the study early” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.